{"nctId":"NCT03078855","briefTitle":"A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma","startDateStruct":{"date":"2017-09-07","type":"ACTUAL"},"conditions":["Follicular Lymphoma","Small Lymphocytic Lymphoma","Marginal Zone Lymphoma","Mucosal-Associated Lymphoid Tissue Lymphoma"],"count":211,"armGroups":[{"label":"Vitamin D plus rituximab","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Vitamin D","Biological: Rituximab"]},{"label":"Placebo plus rituximab","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Rituximab","Other: Placebo"]}],"interventions":[{"name":"Vitamin D","otherNames":["Cholecalciferol"]},{"name":"Rituximab","otherNames":["Rituxan"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nEach of the following criteria must be met in order for a patient to be considered eligible for registration:\n\n* Biopsy proven (with hematopathology review at one of the participating sites to confirm correct histology in accordance with World Health Organization) indolent lymphoma to include the following diagnoses:\n\n  * Grade 1, 2, or 3a follicular lymphoma\n  * Small lymphocytic lymphoma (CLL excluded)\n  * Marginal zone lymphoma (nodal or splenic)\n  * Mucosal-associated lymphoid tissue\n* Measurable disease defined by Lugano criteria\n* No prior anti-lymphoma systemic therapy; prior radiation therapy allowed\n* Age 18 or over\n* Ann Arbor stages II, III or IV\n* Patients with follicular lymphoma must have PET FDG-avid lymphoma and fulfill Low tumor burden by Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria:\n\n  * No mass \\> 7 cm\n  * \\< 3 distinct masses of greater than 3 cm\n  * No B symptoms\n  * No splenomegaly \\> 16 cm by computed tomography (CT) scan\n  * No risk of vital organ compression\n  * No leukemic phase \\> 5000/µl circulating lymphocytes (except for in patients with splenic marginal zone diagnosis)\n  * No cytopenias (platelets \\< 100,000/µl, hemoglobin \\< 10 g/dl, or absolute neutrophil count \\< 1500/µl)\n\nExclusion Criteria:\n\nThe following criteria will prevent inclusion of an inappropriate subject into the trial:\n\n* Osteoporosis requiring prescription treatment\n* Known symptomatic primary hyperparathyroidism\n* Hypercalcemia defined as above the institutional normal range (corrected for albumin when albumin levels are below normal)\n* History of calcium-related kidney stones\n* Creatinine \\> 1.5X above upper limit of normal\n* Women who are known to be pregnant or who plan to become pregnant while on rituximab treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event Free Survival","description":"Event free survival (EFS) was defined as the time from randomization to lack of response at week 13, initiation of a new treatment, disease progression defined by Lugano criteria, or death, right-censored by time of last follow-up. Per Lugano criteria, progression is defined as a new FDG-avid lesion or an increase in intensity from baseline, an increase by \\>= 50% in lesion diameters, a new lymph node \\> 1.5 cm in any axis or a new extranodal site \\> 1.0 cm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"49.5","spread":null}]}]}]},{"type":"SECONDARY","title":"All-Cause Mortality","description":"Number of participants who died from any cause between day 1 of treatment and the time of last follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Response at 13 Weeks","description":"Participants had imaging performed at week 13 to assess response to treatment. A response was defined as partial (PR) or complete response (CR) according to Lugano criteria. Per Lugano criteria for target lesions: PR includes reduced metabolic uptake or a ≥ 50% decrease in the sum of the products of the diameters compared to baseline. CR includes metabolic score of 1, 2 or 3 (out of 5) with or without residual mass or regression of target lesions to ≤ 1.5 cm in the longest dimension.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":135},"commonTop":["Infusion related reaction","Fatigue","Headache","Injection site reaction","Other - COVID19"]}}}